Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.
SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company focused on the research, discovery, and development of drugs for central nervous system disorders. Founded in 2011 and headquartered in Seongnam, the company is advancing several clinical candidates, including Cenobamate for epilepsy, Solriamfetol for excessive daytime sleepiness, and Carisbamate for Lennox-Gastaut syndrome. Additionally, Relenopride is in Phase 2 trials for a rare neurological disease, while SKL13865, SKL20540, SKL-PSY, and SKL24741 are in various early-phase trials for conditions such as attention deficit/hyperactivity disorder, schizophrenia, bipolar disorder, and epilepsy. SK Biopharmaceuticals aims to become a leading specialty pharmaceutical company by developing innovative therapies for CNS and metabolic disorders, alongside providing specialized pharmaceutical manufacturing services.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.
Everlife Asia is a buy-and-build platform aimed to provide complete solutions for the healthcare and research industries.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, specializing in the development of specific and selective antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create novel monoclonal antibody and cell-based therapeutics. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate aimed at treating soft tissue and bone sarcoma, non-small cell lung cancer, and other tumors. BioAtla's pipeline also includes BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, which addresses various cancers such as renal cell carcinoma and bladder cancer. The company's innovative approach enhances drug selectivity for cancer tissues, potentially improving safety and expanding treatment options for previously untreatable cancers. BioAtla holds over 150 issued patents and patent applications, underscoring its commitment to developing safer and more effective cancer therapies.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on developing treatments for severe inflammation and autoimmune diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, aimed at treating conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. The company is also advancing additional candidates, including VIB4920 for kidney transplantation rejection and Sjögren’s syndrome, as well as VIB7734 for cutaneous lupus erythematosus. Viela Bio has formed a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, the company is dedicated to addressing unmet medical needs in the field of autoimmune disorders.
Sai Life Sciences Ltd. specializes in the discovery, contract development, and manufacturing of pharmaceuticals for clients in the biotechnology and pharmaceutical sectors. The company offers a comprehensive range of services, including discovery solutions such as synthetic and medicinal chemistry, toxicology, and pharmacology, as well as development services like analytical method validation, stability studies, and formulation development. Additionally, Sai Life Sciences provides manufacturing capabilities for late-phase and commercial products, along with technology transfer services. With a presence in key markets including India, the United States, the European Union, and Japan, the company has established research and manufacturing facilities in Hyderabad, Pune, Bidar, Cambridge, and Manchester. Founded in 1999 and formerly known as SAI Advantium Pharma Limited, Sai Life Sciences is focused on helping its clients accelerate the development of innovative medicines while minimizing risks and costs.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Forbius, also known as Formation Biologics, is a clinical-stage company focused on designing and developing biotherapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, Forbius specializes in creating agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. The company aims to provide highly active inhibitors of these validated pathways, utilizing its expertise in biology and protein engineering technologies to develop novel therapeutic options. Through their innovative approach, Forbius seeks to significantly improve patient outcomes and transform the treatment landscape for challenging diseases.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.
Sloning BioTechnology has developed a unique and patented technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability and production cost on an industrial scale robotic system the Slonomics technology platform.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
Locus Pharmaceuticals, Inc. is focused on the development of novel small molecule therapeutic drugs aimed at addressing significant unmet medical needs. The company utilizes a fragment-based computational drug design technology to discover and develop oral drug therapies. Its pipeline includes candidates targeting direct and allosteric kinase inhibitors for treating cancer and inflammatory diseases. Founded in 1998 and based in Blue Bell, Pennsylvania, Locus Pharmaceuticals was previously known as Locus Discovery, Inc. and was once a subsidiary of Sarnoff Corporation.
Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.
Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.
Lux Biosciences, Inc. is a biotechnology company based in Jersey City, New Jersey, focused on developing medications for ophthalmic diseases. Founded in 2005, the company offers a range of innovative treatments, including LX201, a silicone matrix ocular implant that delivers cyclosporine A to the eye for a duration of one year. Additionally, Lux Biosciences produces Luveniq, an oral formulation of the calcineurin inhibitor voclosporin, as well as LX212, a bioerodible polymer implant containing voclosporin. The company also provides LX214, a topical formulation of voclosporin designed to address dry eye conditions. Through these products, Lux Biosciences aims to improve treatment options for serious eye diseases.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.
Sloning BioTechnology has developed a unique and patented technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability and production cost on an industrial scale robotic system the Slonomics technology platform.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
Biovitrum is an international pharmaceutical company based in Sweden, specializing in the development and marketing of biotechnology therapeutics. The company focuses on areas with significant unmet medical needs, including hemophilia, inflammation and autoimmune diseases, cancer supportive care, and malabsorption. With expertise in scientific innovation, Biovitrum develops small molecule drugs and recombinant protein therapeutics, particularly targeting metabolic disorders and oncology. The company has approximately 400 employees and generates revenues of around SEK 1.2 billion. In 2009, Biovitrum merged with Swedish Orphan, resulting in a rebranding to Swedish Orphan Biovitrum, further strengthening its position in the global pharmaceutical market.
Genizon Biosciences Inc. discovers genes and biomarkers in common diseases using genome wide association studies (GWAS), leveraging its proven and proprietary technology platform and access to patients from the Quebec Founder Population.